TGTX TG Therapeutics Corp: Net earnings per one share for the last twelve months

The growth of TG Therapeutics, Inc. (TGTX) is driven by the launch of Briumvi and the potential for mergers within the biotech sector. On GURU.Markets, the 12-month annual growth in earnings per share reflects performance dynamics where the parameter value equals -76.40. Antibody production is outsourced under strict quality control. However, the capital intensity of clinical trials and rigorous regulatory oversight create significant barriers to new developments.
TG Pharma - analytical breakdowns and key metrics (TGTX)

Earnings per share dynamics serve as a key filter during portfolio stress testing, allowing for an assessment of real capital generation efficiency. This metric measures the percentage change in net income over the last twelve months relative to the previous year; by analyzing the EPS YoY TTM growth trajectory, an investor can see the resilience of TG Therapeutics, Inc. (TGTX), whose sales of vital sclerosis treatments remain independent of economic cycles.